再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09688 再鼎医药

未开盘 04-14 16:08:20

16.920

+0.570

+3.49%

最高17.000	最低16.380	成交量1,295万
今开16.630	昨收16.350	日振幅3.79%
总市值191.87亿	流通市值191.87亿	总股本11.34亿
成交额2.17亿	换手率1.14%	流通股本11.34亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09688","market":"HK","secType":"STK","nameCN":"再鼎医药","latestPrice":16.92,"timestamp":1776154100008,"preClose":16.35,"halted":0,"volume":12950400,"delay":0,"changeRate":0.03486238532110093,"floatShares":1134000000,"shares":1134000000,"eps":-1.2553421481388645,"marketStatus":"未开盘","change":0.57,"latestTime":"04-14 16:08:20","open":16.63,"high":17,"low":16.38,"amount":216901325,"amplitude":0.03792,"askPrice":16.92,"askSize":3600,"bidPrice":16.91,"bidSize":93400,"shortable":3,"etf":0,"ttmEps":-1.2553421481388645,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776216600000},"marketStatusCode":0,"adr":0,"listingDate":1601222400000,"exchange":"SEHK","adjPreClose":16.35,"openAndCloseTimeList":[[1776130200000,1776139200000],[1776142800000,1776153600000]],"volumeRatio":0.7493062043834198,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09688/wiki","defaultTab":"wiki","newsList":[{"id":"2627498112","title":"港股异动 | 再鼎医药(09688)涨超3% 近日与安进达成全球临床合作 Zoci正处于全球注册性临床III期阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2627498112","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627498112?lang=zh_cn&edition=full","pubTime":"2026-04-14 09:46","pubTimestamp":1776131184,"startTime":"0","endTime":"0","summary":"消息面上，近日，再鼎医药官微宣布，公司与安进公司达成一项全球临床研究合作，旨在评估再鼎医药处于临床阶段的靶向delta样配体3的抗体药物偶联物zocilurtatug pelitecan联合安进IMDELLTRA，一款靶向DLL3的双特异性T细胞衔接器疗法，用于治疗广泛期小细胞肺癌患者。作为该合作协议的一部分，安进将申办一项全球1b期研究，评估zoci联合IMDELLTRA在ES-SCLC患者中的安全性和有效性。再鼎医药将保留zoci的完整所有权，并将向安进提供临床研究用药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0002141913.USD","LU2112291526.USD","LU2468319806.SGD","LU2488822045.USD","LU0109394709.USD","LU0289739699.SGD","BK1588","BK1574","IE00BFTCPJ56.SGD","BK4581","LU0868494617.USD","LU0122379950.USD","LU0889565916.HKD","BK1161","BK4534","AMGN","III","SG9999001440.SGD","BK4588","VXUS","LU0058720904.USD","LU1023059063.AUD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","BK4526","BK4531","LU2242652126.USD","BK4585","BK4566","LU0320765992.SGD","LU2242646821.SGD","IE00B4R5TH58.HKD","ZLAB","BK4548","BK4139","BK4134","09688","BK4599","LU1061106388.HKD","LU1571399168.USD","LU1057294990.SGD","LU1983299246.USD","IE0009355771.USD","IE00B2B36J28.USD","LU2089984988.USD","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624313635","title":"持续打击医保药品领域违法违规问题；中国首个原创核药获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2624313635","media":"21世纪经济报道","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624313635?lang=zh_cn&edition=full","pubTime":"2026-04-03 08:02","pubTimestamp":1775174556,"startTime":"0","endTime":"0","summary":"政策动向国家医保局持续开展打击医保药品领域违法违规问题专项行动近日国家医保局办公室印发《关于深入开展打击医保药品领域违法违规问题专项行动的通知》，对持续打击倒卖医保“回流药”等违法违规问题进行专门部署。《通知》要求，自2026年4月起，以药品追溯码疑点线索核查为抓手，在全国范围内继续深入开展打击医保药品领域违法违规问题专项行动。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604033694126468.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604033694126468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","AGIX","06978","BK4080","BK0239","LU2488822045.USD","BK1588","BK1574","BK4231","09688","603168","ADC","688520","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624005385","title":"再鼎医药(09688)授出购股权、受限制股份单位及业绩股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2624005385","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624005385?lang=zh_cn&edition=full","pubTime":"2026-04-02 22:49","pubTimestamp":1775141352,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)公布，公司于2026年4月1日(美国东部时间)根据2024年股权激励计划授出部分购股权、受限制股份单位以及业绩股份单位。授出可认购26.85万股美国存托股份的购股权、60.3851万股美国存托股份受限制股份单位及33,781股美国存托股份的业绩股份单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424881.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK4139","09688","ZLAB","BK1588","BK4585","BK4588","LU2488822045.USD","BK1161","BK4548","BK4526","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624222315","title":"再鼎医药宣布达成全球临床研究合作及供应协议，以评估创新性DLL3抗体药物偶联物Zocilurtatug Pelitecan与双特异性T细胞衔接器的联合治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2624222315","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624222315?lang=zh_cn&edition=full","pubTime":"2026-04-02 11:58","pubTimestamp":1775102280,"startTime":"0","endTime":"0","summary":"再鼎医药将保留zoci的完整所有权，并将向安进提供临床研究用药。\" Zoci是靶向DLL3的 ADC，用于小细胞肺癌的治疗。关于Zocilurtatug Pelitecan  Zoci是再鼎医药全球肿瘤研发管线中一款靶向DLL3的新型ADC。Zoci已获得美国FDA授予的治疗SCLC的孤儿药资格认定和快速通道资格认定。IMDELLTRA是首款靶向DLL3的双特异性T细胞衔接器疗法，在上述患者中已验证具有总生存期获益。Zocilurtatug Pelitecan与IMDELLTRA的联合用药方案有望在此优势基础上，进一步改善有效性，同时保持可控的安全性[6]。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4924934_ZH24934_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2488822045.USD","BK1574","BK4588","BK1161","BK4531","BK4585","09688","ZLAB","BK4526","BK1588","BK4139","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624524927","title":"再鼎医药午前涨近5% 与安进公司达成一项全球临床研究合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2624524927","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624524927?lang=zh_cn&edition=full","pubTime":"2026-04-02 11:37","pubTimestamp":1775101020,"startTime":"0","endTime":"0","summary":"　　再鼎医药午前涨超4%，截至发稿，股价上涨4.82%，现报15.88港元，成交额2.88亿港元。　　作为该合作协议的一部分，安进将申办一项全球1b期研究，评估zoci联合IMDELLTRA在ES-SCLC患者中的安全性和有效性。再鼎医药将保留zoci的完整所有权，并将向安进提供临床研究用药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-04-02/doc-inhtaraa1102717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BJJMRZ35.SGD","BK4139","BK4581","LU2242652126.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","LU2112291526.USD","LU0289739699.SGD","LU0122379950.USD","SG9999001440.SGD","IE0002141913.USD","LU0109394709.USD","BK4585","BK4526","BK1161","BK1588","LU0868494617.USD","LU2242646821.SGD","LU0320765992.SGD","BK4533","BK4534","IE00BJT1NW94.SGD","LU2468319806.SGD","LU1983299246.USD","IE00B4R5TH58.HKD","LU0058720904.USD","BK1574","09688","LU1061106388.HKD","BK4548","LU2488822045.USD","LU1023059063.AUD","LU2089984988.USD","LU0889565916.HKD","LU1571399168.USD","ZLAB","BK4588","BK4531","BK4599","LU1057294990.SGD","AMGN","IE00B2B36J28.USD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624452674","title":"港股再鼎医药涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624452674","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624452674?lang=zh_cn&edition=full","pubTime":"2026-04-02 09:58","pubTimestamp":1775095138,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月2日，再鼎医药(09688.HK)涨超4%，截至发稿涨4.22%，报15.79港元，成交额9800.73万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604023693054050.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"6c2eecd8186c1b91dbc836fcc084ea03","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604023693054050.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","BK4531","BK4548","09688","BK4585","ZLAB","VXUS","BK4139","BK4526","LU2488822045.USD","BK1161","BK1588","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119669418","title":"异动解读 | 再鼎医药与安进达成临床合作，盘中大涨5.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=1119669418","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119669418?lang=zh_cn&edition=full","pubTime":"2026-04-02 09:52","pubTimestamp":1775094768,"startTime":"0","endTime":"0","summary":"再鼎医药今日盘中大涨5.94%，引起了市场的广泛关注。消息面上，再鼎医药宣布与安进公司达成一项全球临床研究合作，旨在评估再鼎医药处于临床阶段的靶向DLL3的抗体药物偶联物zoci联合安进的塔拉妥单抗，用于治疗广泛期小细胞肺癌患者。根据合作协议，安进将申办一项全球1b期研究，评估该联合疗法的安全性和有效性。再鼎医药将保留zoci的完整所有权，并向安进提供临床研究用药。此次合作被视为公司研发管线的重要进展，增强了市场对其未来增长潜力的信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132833045","title":"再鼎医药宣布全球临床试验合作与供应协议，评估新型Dll3 ADC药物Zocilurtatug Pelitecan联合双特异性T细胞衔接疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1132833045","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132833045?lang=zh_cn&edition=full","pubTime":"2026-04-01 19:30","pubTimestamp":1775043024,"startTime":"0","endTime":"0","summary":"再鼎医药近日宣布达成一项全球临床试验合作与供应协议，将重点评估其创新药物Zocilurtatug Pelitecan（一种靶向Dll3的抗体药物偶联物）与双特异性T细胞衔接疗法联合应用的临床效果。该合作旨在探索这一联合治疗方案在特定适应症中的潜力，为未来临床开发提供重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","LU2488822045.USD","09688","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623373124","title":"【券商聚焦】中信证券：基本医保基金收支和结余整体保持稳健","url":"https://stock-news.laohu8.com/highlight/detail?id=2623373124","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623373124?lang=zh_cn&edition=full","pubTime":"2026-03-31 08:59","pubTimestamp":1774918794,"startTime":"0","endTime":"0","summary":"2026年2月医保支出同比增速回升，收支剪刀差有所收窄。该机构预计在医保基金监管力度持续加大，DRG/DIP精细化管理的推动下，2026年全年基金结余率或将延续此前节奏略有提升。医疗健康产业政策改革进入密集期，建议持续关注政策驱动下的医疗健康产业投资机会。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977773","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","LU0634319403.HKD","BK1515","HK0000165453.HKD","LU2488822045.USD","09688","BK1161","IE00B543WZ88.USD","BK1583","BK1147","BK1100","03933","LU0405327494.USD","IE00BPRC5H50.USD","LU1969619763.USD","BK0028","02268","LU2399975544.HKD","LU2495084118.USD","01530","LU0348783233.USD","LU0348766576.USD","LU1328615791.USD","01789","06821","LU1255011170.USD","600030","LU0405327148.USD","LU1719994722.HKD","LU1770034418.SGD","06160","LU2148510915.USD","LU0307460666.USD","LU0348735423.USD","BK1588","BK1564","02228","BK1617","02196","01099","BK1191","LU1115378108.SGD","LU1303224171.USD","BK1593","BK0276","LU1997245177.USD","06030","BK0012","LU2476274308.USD","02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622570897","title":"再鼎医药(09688)发布年度业绩 总收入同比增加15%至4.6亿美元 各产品管线进展积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2622570897","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622570897?lang=zh_cn&edition=full","pubTime":"2026-03-27 07:20","pubTimestamp":1774567240,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药 发布截至2025年12月31日止财政年度全年业绩，产品收入净额增加15%至4.57亿美元，主要是由于鼎优乐的销售增加及纽再乐的销售增加。每股基本及摊薄亏损为0.16美元。于2025年，公司的财务业绩持续强势，总收入较上年增加15%至4.6亿美元，而净亏损则减少32%至1.76亿美元。于2026年，公司预计收入将持续增长，主要得益于现有商业化产品以及近期获批并预计于今年内上市的产品或新适应证。公司的各产品管线方面亦继续取得进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420133.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"再鼎医药(09688)发布年度业绩 总收入同比增加15%至4.6亿美元 各产品管线进展积极","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","BK4139","BK1574","BK4588","LU2488822045.USD","BK1161","BK4526","09688","BK4548","ZLAB","BK4585","BK4531"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2621095723","title":"【券商聚焦】交银国际：CXO行情持续回暖 料板块估值倍数合理","url":"https://stock-news.laohu8.com/highlight/detail?id=2621095723","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621095723?lang=zh_cn&edition=full","pubTime":"2026-03-23 10:25","pubTimestamp":1774232735,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，多重利好因素共振下，2025年以来CXO行情持续回暖。该机构建议重点关注标的细分赛道成长力、核心能力布局、盈利和订单增长能见度、地缘风险敞口及估值上升空间。基于此，该机构首推药明合联，首次覆盖并重点推荐凯莱英和康龙化成。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977006","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2476274720.SGD","BK1207","LU1770034418.SGD","LU0348735423.USD","LU0417516902.SGD","LU0634319403.HKD","01530","06160","BK1583","LU2328871848.SGD","02228","BK1585","BK1191","01789","BK1161","BK1588","CXO","09926","IE00B543WZ88.USD","02367","LU0417516738.SGD","LU1303224171.USD","02196","LU2399975544.HKD","LU2476274308.USD","03329","BK1617","LU0348784397.USD","02268","BK1574","IE00BPRC5H50.USD","09688","06821","03933","LU1115378108.SGD","LU2488822045.USD","LU0348767384.USD","01099","LU0540923850.HKD","LU1794554557.SGD","LU0307460666.USD","BK1141","BK1197","BK1593","LU0348827113.USD","LU0417516571.SGD","BK1500","LU0348766576.USD","LU1719994722.HKD","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619546907","title":"再鼎医药(09688.HK)拟3月26日(美国东部时间)/3月27日(香港时间)举行董事会会议以审批年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2619546907","media":"中金财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619546907?lang=zh_cn&edition=full","pubTime":"2026-03-16 22:07","pubTimestamp":1773670021,"startTime":"0","endTime":"0","summary":"格隆汇3月16日丨再鼎医药(09688.HK)公告，董事会将于2026年3月26日(星期四，美国东部时间)/2026年3月27日(星期五，香港时间)审议及批准(其中包括)根据香港联合交易所有限公司证券上市规则编制的公司及其附属公司截至2025年12月31日止年度的年度业绩及其发布。\r\n\r\n　　公司先前已公布其根据美国公认会计准则编制的年度业绩，并于2026年2月26日(星期四，美国东部时间/香港时间)以表格10-K向美国证券交易委员会(\"美国证交会\")提交其截至2025年12月31日止年度的年度报告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260316/32072706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU2488822045.USD","BK1588","BK1574","BK4526","09688","BK4585","BK1161","BK4588","BK4139","ZLAB","BK4548","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619190413","title":"再鼎医药(09688)：授出购股权、受限制股份单位及业绩股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2619190413","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619190413?lang=zh_cn&edition=full","pubTime":"2026-03-13 21:24","pubTimestamp":1773408240,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，本公司于授出日期根据2024年股权激励计划授出35.34万份购股权、3.24万股受限制股份单位以及17.54万股业绩股份单位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413883.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","BK1161","BK4588","09688","BK4585","BK1574","BK4548","BK4526","LU2488822045.USD","BK4139","BK4531","ZLAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619594441","title":"每日卖空追踪 | 再鼎医药 03月12日卖空量成交57.47万股，卖空比例为5.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619594441","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619594441?lang=zh_cn&edition=full","pubTime":"2026-03-12 16:30","pubTimestamp":1773304243,"startTime":"0","endTime":"0","summary":"再鼎医药北京时间03月12日，跌2.85%，卖空量成交57.47万股，较上一交易日增加81.24%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312163629a46376ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312163629a46376ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09688","LU2488822045.USD","BK1588","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618183638","title":"每日卖空追踪 | 再鼎医药 03月11日卖空量成交14.71万股，卖空比例为2.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618183638","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618183638?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:30","pubTimestamp":1773217842,"startTime":"0","endTime":"0","summary":"再鼎医药北京时间03月11日，涨0.07%，卖空量成交14.71万股，较上一交易日减少79.78%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163627a6b79736&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163627a6b79736&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","LU2488822045.USD","09688","BK1588","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618862761","title":"再鼎医药(09688)授出购股权、受限制股份单位及业绩股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2618862761","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618862761?lang=zh_cn&edition=full","pubTime":"2026-03-09 22:42","pubTimestamp":1773067323,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)公布，公司于授出日期根据2024年股权激励计划授出可认购37.422万股美国存托股份的购股权、12.162万股美国存托股份受限制股份单位以及18.2428万股美国存托股份的业绩股份单位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411864.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1161","LU2488822045.USD","BK1574","BK4526","09688","BK4585","ZLAB","BK1588","BK4548","BK4531","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618036246","title":"每日卖空追踪 | 再鼎医药 03月09日卖空量成交30.84万股，卖空比例为3.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618036246","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618036246?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:30","pubTimestamp":1773045042,"startTime":"0","endTime":"0","summary":"再鼎医药北京时间03月09日，跌4.2%，卖空量成交30.84万股，较上一交易日减少39.65%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163619a6b1c9f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163619a6b1c9f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","BK1161","09688","BK1574","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618036906","title":"再鼎医药03月09日遭主力抛售719.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618036906","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618036906?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:15","pubTimestamp":1773044156,"startTime":"0","endTime":"0","summary":"03月09日, 再鼎医药股价跌4.20%，报收14.83元，成交金额1.3亿元，换手率0.79%，振幅2.20%，量比0.85。再鼎医药今日主力资金净流出719.0万元，上一交易日主力净流出96.7万元。该股近5个交易日上涨4.47%，主力资金累计净流入447.1万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入6974.9万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309162050a45ad8e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309162050a45ad8e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","BK1588","BK1574","09688","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617919503","title":"【券商聚焦】交银国际：医药公司业绩兑现有望催化板块行情","url":"https://stock-news.laohu8.com/highlight/detail?id=2617919503","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617919503?lang=zh_cn&edition=full","pubTime":"2026-03-06 09:08","pubTimestamp":1772759313,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际发布医药行业周报，2026年以来，内资通过港股通持有医药股的比例呈现先降后升态势，当前水平与年初持平，外资持仓则有所提升。本周内资继续加仓创新药产业链和器械标的，外资则重点布局创新药企及CXO企业。年报季临近，本周各公司业绩预告陆续发布，该机构建议持续关注财务表现超预期、盈利路径清晰的公司，其业绩兑现有望催化板块行情。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976027","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2328871848.SGD","LU0348735423.USD","02196","LU2778985437.USD","LU0640798160.USD","LU1719994722.HKD","LU0348783233.USD","02228","BK1207","03329","BK1515","LU0348784397.USD","LU0540923850.HKD","LU2488822045.USD","IE00B5MMRT66.SGD","BK1197","LU0561508036.HKD","LU1115378108.SGD","01530","09926","09688","LU1770034418.SGD","SG9999014674.SGD","LU0417516571.SGD","LU2476274308.USD","BK1593","BK1141","HK0000165453.HKD","06160","BK1191","LU0348766576.USD","LU0588546209.SGD","02268","LU1794554557.SGD","LU1961090484.USD","IE00BPRC5H50.USD","LU1303224171.USD","09939","02367","SG9999004311.SGD","03933","LU2399975544.HKD","LU2476274720.SGD","BK1574","BK1585","01099","LU0348825331.USD","01789","159938","LU0348827113.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617526522","title":"再鼎医药(09688)授出购股权及受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2617526522","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617526522?lang=zh_cn&edition=full","pubTime":"2026-03-05 22:54","pubTimestamp":1772722453,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，公司于授出日期根据2024年股权激励计划向4名承授人授出可认购合共8万股美国存托股份的购股权并向9名承授人授出涉及合共12.344万股美国存托股份的受限制股份单位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410705.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09688","BK4548","BK4585","BK1588","BK1161","BK4139","BK4531","ZLAB","BK4588","BK4526","LU2488822045.USD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":0.0722},{"period":"1month","weight":0.1832},{"period":"3month","weight":0.093},{"period":"6month","weight":-0.2744},{"period":"1year","weight":-0.3051},{"period":"ytd","weight":0.2396}],"compareEarnings":[{"period":"1week","weight":0.0301},{"period":"1month","weight":0.016},{"period":"3month","weight":-0.0418},{"period":"6month","weight":-0.0006},{"period":"1year","weight":0.208},{"period":"ytd","weight":0.0094}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"再鼎医药有限公司是一家主要从事生物制药业务的控股公司。该公司致力于通过产品的发现、开发和商业化解决肿瘤、免疫、神经科学和感染性疾病领域未被满足的医疗需求。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物，其中包括“则乐”、“OPTUNE”、“擎乐”、“纽再乐”及“卫伟迦”等。该公司在国内市场和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.017355},{"month":2,"riseRate":0.666667,"avgChangeRate":0.068855},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.098942},{"month":4,"riseRate":0.666667,"avgChangeRate":0.066517},{"month":5,"riseRate":0.4,"avgChangeRate":-0.024133},{"month":6,"riseRate":0.4,"avgChangeRate":-0.013792},{"month":7,"riseRate":0.8,"avgChangeRate":0.065752},{"month":8,"riseRate":0.6,"avgChangeRate":-0.021717},{"month":9,"riseRate":0.4,"avgChangeRate":-0.054178},{"month":10,"riseRate":0.5,"avgChangeRate":-0.051338},{"month":11,"riseRate":0.5,"avgChangeRate":0.047251},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.024481}],"exchange":"SEHK","name":"再鼎医药","nameEN":"ZAI LAB"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,09688,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}